Letter to the Editor Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/dentistry.2.009
Oral Lesions in the COVID-19 Positive Individuals – An Update
Ambreen Rehman1, Ibrahim O. Bello2,3, Ehsanul Hoque Apu4,5, *
- 1Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 2Department of Oral Medicine and Diagnostic Sciences, King Saud University, Riyadh, Saudi Arabia.
- 3Department of Pathology, University of Helsinki, Helsinki, Finland
- 4Faculty of Biochemistry and Molecular Medicine, Laboratory of Developmental Biology, University of Oulu, Aapistie 5A, 90220 Oulu, Finland
- 5Institute of Quantitative Health Science (IQ), Department of Biomedical Engineering, Michigan State University, East Lansing, MI 48824, USA
Corresponding Author
Ehsanul Hoque Apu, ehsanul.hoqueapu@oulu.fi; hoqueapu@msu.edu
Received Date: July 01, 2020
Accepted Date: August 21, 2020
Rehman A, Bello IO, Apu EH. Oral Lesions in the COVID-19 Positive Individuals – An Update. Arch Dent. 2020; 2(1):8-9.
Copyright: © 2020 Rehman A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
COVID-19 Clinical Research
While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.
Therapeutic Values of Ketamine for COVID-19-Cared Patients: An Expert’s Point of View
Ketamine has long been used in the field of anesthesia [1]. Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.
A Bioinformatics Protocol for Rational Design of Peptide Vaccines and the COVID-19 Rampage
The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.
Lessons Learnt from COVID-19: How Can We Prepare for Another Pandemic?
Five months into the COVID-19 pandemic, the U.S. death toll from the virus has now surpassed 100,000 people. Many more cases remain nationwide, while an unknown number of patients currently harbor the virus asymptomatically. While health officials are now optimistic regarding the decline in prevalence and number of deaths due to COVID-19 and the possibility of a vaccine by the fall, we cannot lose sight of the bigger picture: the next pandemic.
Safety of Using Rituximab Therapy During COVID-19 Pandemic
Our modern world is facing extraordinary circumstances while passing through a serious pandemic caused by the novel coronavirus (COVID-19) which may lead to multi-organ system failure & death. Bcell depletion could compromise antiviral immunity, which makes the safety of rituximab use in the COVID19 era unclear.